A000220 Stock Overview
Develops and markets pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Yuyu Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,550.00 |
| 52 Week High | ₩6,730.00 |
| 52 Week Low | ₩3,900.00 |
| Beta | 0.51 |
| 1 Month Change | 8.33% |
| 3 Month Change | -2.78% |
| 1 Year Change | -14.63% |
| 3 Year Change | -41.82% |
| 5 Year Change | -19.82% |
| Change since IPO | 438.68% |
Recent News & Updates
Unpleasant Surprises Could Be In Store For Yuyu Pharma, Inc.'s (KRX:000220) Shares
Nov 13
Concerns Surrounding Yuyu Pharma's (KRX:000220) Performance
Aug 24Pinning Down Yuyu Pharma, Inc.'s (KRX:000220) P/S Is Difficult Right Now
Aug 07Recent updates
Unpleasant Surprises Could Be In Store For Yuyu Pharma, Inc.'s (KRX:000220) Shares
Nov 13Concerns Surrounding Yuyu Pharma's (KRX:000220) Performance
Aug 24Pinning Down Yuyu Pharma, Inc.'s (KRX:000220) P/S Is Difficult Right Now
Aug 07Here's Why Yuyu Pharma (KRX:000220) Has A Meaningful Debt Burden
Apr 02Should Yuyu Pharma, Inc. (KRX:000220) Be Part Of Your Dividend Portfolio?
Mar 08The Yuyu Pharma (KRX:000220) Share Price Has Gained 12% And Shareholders Are Hoping For More
Feb 10
We Wouldn't Rely On Yuyu Pharma's (KRX:000220) Statutory Earnings As A Guide
Jan 07Yuyu Pharma (KRX:000220) Seems To Use Debt Quite Sensibly
Dec 20Would Yuyu Pharma, Inc. (KRX:000220) Be Valuable To Income Investors?
Dec 03Shareholder Returns
| A000220 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 2.4% | -1.7% | -3.7% |
| 1Y | -14.6% | 0.1% | -10.4% |
Return vs Industry: A000220 underperformed the KR Pharmaceuticals industry which returned 0.1% over the past year.
Return vs Market: A000220 underperformed the KR Market which returned -10.4% over the past year.
Price Volatility
| A000220 volatility | |
|---|---|
| A000220 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A000220 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A000220's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 253 | Robert Yu | www.yuyu.co.kr |
Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Jecheon-si, South Korea.
Yuyu Pharma, Inc. Fundamentals Summary
| A000220 fundamental statistics | |
|---|---|
| Market cap | ₩73.63b |
| Earnings (TTM) | ₩8.56b |
| Revenue (TTM) | ₩134.79b |
8.6x
P/E Ratio0.5x
P/S RatioIs A000220 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A000220 income statement (TTM) | |
|---|---|
| Revenue | ₩134.79b |
| Cost of Revenue | ₩83.69b |
| Gross Profit | ₩51.10b |
| Other Expenses | ₩42.55b |
| Earnings | ₩8.56b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 528.76 |
| Gross Margin | 37.91% |
| Net Profit Margin | 6.35% |
| Debt/Equity Ratio | 26.4% |
How did A000220 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 01:14 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Yuyu Pharma, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |